AU2021297216B2 - Methods of treating cancer using heteroaryl-biphenyl amide derivatives - Google Patents

Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Info

Publication number
AU2021297216B2
AU2021297216B2 AU2021297216A AU2021297216A AU2021297216B2 AU 2021297216 B2 AU2021297216 B2 AU 2021297216B2 AU 2021297216 A AU2021297216 A AU 2021297216A AU 2021297216 A AU2021297216 A AU 2021297216A AU 2021297216 B2 AU2021297216 B2 AU 2021297216B2
Authority
AU
Australia
Prior art keywords
cancer
group
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021297216A
Other languages
English (en)
Other versions
AU2021297216A1 (en
Inventor
Shijie Li
Marta VILALTA-COLOMER
Yibin Zeng
Penglie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2021297216A1 publication Critical patent/AU2021297216A1/en
Application granted granted Critical
Publication of AU2021297216B2 publication Critical patent/AU2021297216B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021297216A 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives Active AU2021297216B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23
US63/042,807 2020-06-23
PCT/US2021/038339 WO2021262627A1 (en) 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Publications (2)

Publication Number Publication Date
AU2021297216A1 AU2021297216A1 (en) 2023-02-02
AU2021297216B2 true AU2021297216B2 (en) 2025-10-16

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021297216A Active AU2021297216B2 (en) 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Country Status (14)

Country Link
US (3) US20210393759A1 (cg-RX-API-DMAC7.html)
EP (1) EP4167991A4 (cg-RX-API-DMAC7.html)
JP (1) JP7804596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040993A (cg-RX-API-DMAC7.html)
CN (1) CN116472045B (cg-RX-API-DMAC7.html)
AU (1) AU2021297216B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022026397A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187605A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003716A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000703A2 (cg-RX-API-DMAC7.html)
IL (1) IL299206A (cg-RX-API-DMAC7.html)
MX (1) MX2022016554A (cg-RX-API-DMAC7.html)
TW (1) TW202216694A (cg-RX-API-DMAC7.html)
WO (1) WO2021262627A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
ES3068390T3 (en) * 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076691A1 (en) * 2019-10-16 2021-04-22 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673919B2 (en) * 2009-03-27 2014-03-18 Ardea Biosciences, Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US10308644B2 (en) * 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
US10919852B2 (en) * 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
EP3735410A4 (en) * 2017-10-19 2021-11-03 Tempest Therapeutics, Inc. PICOLINAMIDE COMPOUNDS
WO2019160882A1 (en) * 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019165043A2 (en) * 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) * 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076691A1 (en) * 2019-10-16 2021-04-22 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases

Also Published As

Publication number Publication date
EP4167991A1 (en) 2023-04-26
US20240115682A1 (en) 2024-04-11
CN116472045B (zh) 2025-05-13
EP4167991A4 (en) 2024-07-24
TW202216694A (zh) 2022-05-01
WO2021262627A1 (en) 2021-12-30
CA3187605A1 (en) 2021-12-30
IL299206A (en) 2023-02-01
MX2022016554A (es) 2023-04-10
CL2022003716A1 (es) 2023-06-30
KR20230040993A (ko) 2023-03-23
CO2023000703A2 (es) 2023-01-26
BR112022026397A2 (pt) 2023-03-14
US20250090646A1 (en) 2025-03-20
JP7804596B2 (ja) 2026-01-22
AU2021297216A1 (en) 2023-02-02
JP2023531970A (ja) 2023-07-26
CN116472045A (zh) 2023-07-21
US20210393759A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
US20250090646A1 (en) Methods of treating cancer using heteroaryl-biphenyl amide derivatives
US11691985B2 (en) Macrocyclic immunomodulators
US12533354B2 (en) Triaryl compounds for treatment of PD-L1 diseases
US11485708B2 (en) Compounds for treatment of PD-L1 diseases
US11759458B2 (en) Indane-amines as PD-L1 antagonists
JP2024534184A (ja) 新規ras阻害剤
EP3996711B1 (en) Indanes as pd-l1 inhibitors
CA3226855A1 (en) Treatment for neuroinflammatory disorders
EA049712B1 (ru) Способы лечения рака с использованием производных гетероарилбифениламида
CA3152329C (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CA3145303C (en) Indanes as pd-l1 inhibitors
CA3071951C (en) Macrocyclic immunomodulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)